









Markets
/
Stocks
/
nasdaq-pvla
/

Palvella Therapeutics Inc

PVLA

77.830USD

-0.800-1.02%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

860.77MMarket Cap

LossP/E TTM



Palvella Therapeutics Inc

77.830

-0.800-1.02%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Palvella Therapeutics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Palvella Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

91 / 407

Overall Ranking

213 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 13 analysts

Buy

Current Rating

91.922

Target Price

+18.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Palvella Therapeutics Inc Highlights

StrengthsRisks

Palvella Therapeutics, Inc., formerly Pieris Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is in the Phase III SELVA clinical trial in microcystic lymphatic malformations (microcystic LMs) and a Phase II trial in cutaneous venous malformations. It is also engaged in developing treatment for other serious, functionally debilitating skin diseases driven by the overactivation of the mammalian target of rapamycin (mTOR) pathway.

Undervalued

The company’s latest PE is -14.35, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 6.25M shares, increasing 7.01% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 74.52K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 6.80, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.80

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.98

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Palvella Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 6.73, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -14.35, which is -97.94% below the recent high of -0.30 and -2.58% above the recent low of -14.72.

Score

Industry at a Glance

Previous score

6.73

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 91/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.31, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Palvella Therapeutics Inc is 91.00, with a high of 120.00 and a low of 49.99.

Score

Industry at a Glance

Previous score

8.31

Change

Support & Resistance

No Data

Analyst Rating

Based on 13 analysts

Buy

Current Rating

91.922

Target Price

+18.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Palvella Therapeutics Inc

PVLA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.80, which is higher than the Biotechnology & Medical Research industry's average of 6.46. Sideways: Currently, the stock price is trading between the resistance level at 85.03 and the support level at 68.61, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.93

Change

-0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(4)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.667

Neutral

RSI(14)

59.633

Neutral

STOCH(KDJ)(9,3,3)

61.931

Neutral

ATR(14)

5.080

High Vlolatility

CCI(14)

60.439

Neutral

Williams %R

36.823

Buy

TRIX(12,20)

0.651

Sell

StochRSI(14)

66.536

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

76.822

Buy

MA10

76.147

Buy

MA20

75.238

Buy

MA50

66.127

Buy

MA100

50.776

Buy

MA200

36.637

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 56.52%, representing a quarter-over-quarter decrease of 22.07%. The largest institutional shareholder is The Vanguard, holding a total of 163.81K shares, representing 1.48% of shares outstanding, with 1337.96% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Kaupinen (Wesley H.)

1.61M

Frazier Life Sciences Management, L.P.

722.40K

+4.69%

Suvretta Capital Management, LLC

714.46K

BVF Partners L.P.

696.55K

Integrated Finance Group

559.95K

The Vanguard Group, Inc.

Star Investors

163.81K

+18.33%

Woodline Partners LP

445.62K

+129.50%

BlackRock Institutional Trust Company, N.A.

409.73K

+269.95%

Samsara BioCapital, LLC

339.74K

-50.00%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 4.62, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is -0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.